Spontaneous Nanocrystals/Amorphous MoS Film Induced by Fe Irradiation with Superior Irradiation Tolerance and Tribology Properties.

ACS Appl Mater Interfaces

State Key Laboratory of Solid Lubrication, Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences, Lanzhou 730000, China.

Published: March 2025

High-performance radiation-resistant lubricating materials (RRLMs) with nanostructures hold great promise for enhancing the irradiation tolerance because of their sinking effect of boundaries on defects. Despite recent advances, challenges remain in finding a nanostructure that exhibits both superior irradiation tolerance and excellent lubricant properties. Unlike traditional nanostructured composite materials that required complex predesign, herein, a MoS nanocrystals (NCs)/amorphous dual phase in subirradiation saturation (SIS) state was spontaneously formed during irradiation, exhibiting high irradiation resistance under the synergistic effect of "defect traps" by interfaces and edge dislocation. This nanocrystals (NCs)/amorphous dual phase where each has its own advantages exhibits a significant reduction in both friction coefficient and wear rate even under irradiation damage of 8 dpa, pushing the limit of irradiation performance for current solid lubricants. Furthermore, based on the molecular dynamics (MD) analysis, other factors influencing the intrinsic irradiation tolerance of MoS, such as collision angles and S off-sites, have also been comprehensively investigated to clarify the damage mechanism of MoS. Our findings offer advanced perspectives for the design of high-performance RRLMs, enabled by edge dislocations, S off sites, and crystal orientation, inspiring the fabrication of structural-functional integrated materials in extreme environment applications such as nuclear reactors.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.5c00594DOI Listing

Publication Analysis

Top Keywords

irradiation tolerance
16
irradiation
9
superior irradiation
8
nanocrystals ncs/amorphous
8
ncs/amorphous dual
8
dual phase
8
spontaneous nanocrystals/amorphous
4
mos
4
nanocrystals/amorphous mos
4
mos film
4

Similar Publications

High-performance radiation-resistant lubricating materials (RRLMs) with nanostructures hold great promise for enhancing the irradiation tolerance because of their sinking effect of boundaries on defects. Despite recent advances, challenges remain in finding a nanostructure that exhibits both superior irradiation tolerance and excellent lubricant properties. Unlike traditional nanostructured composite materials that required complex predesign, herein, a MoS nanocrystals (NCs)/amorphous dual phase in subirradiation saturation (SIS) state was spontaneously formed during irradiation, exhibiting high irradiation resistance under the synergistic effect of "defect traps" by interfaces and edge dislocation.

View Article and Find Full Text PDF

Radioresistance remains a major obstacle in cervical cancer treatment, frequently engendering tumor relapse and metastasis. However, the details of its mechanism of action remain largely enigmatic. This study delineates the prospective impacts of short-form human T-cell lymphoma invasion and metastasis 2 (TIAM2S) involving the radiation resistance of cervical cancer.

View Article and Find Full Text PDF

Background: Radiotherapy (RT) is an essential treatment for colorectal cancer (CRC), yet the factors influencing radiosensitivity remain unclear. In the quest to enhance the therapeutic efficacy in CRC, the interplay between genetic mutations and RT sensitivity has emerged as a pivotal yet enigmatic area.

Methods: We harness the fidelity of patient-derived organoids (PDOs) to dissect the molecular landscape of radiosensitivity, with a particular emphasis on BRAF mutations.

View Article and Find Full Text PDF

Efficacy and safety of cadonilimab (PD-1/CTLA-4 bispecific) in combination with chemotherapy in anti-PD-1-resistant recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase 2 trial.

BMC Med

March 2025

Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.

Background: We aimed to evaluate the efficacy and safety of cadonilimab (anti-PD-1 and CTLA-4 bispecific antibody) plus TPC chemotherapy (NAB-paclitaxel, cisplatin or lobaplatin, and capecitabine) in patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) who failed to PD-1 inhibitor-containing regimens.

Methods: In this single-arm, open-label, phase 2 study, RM-NPC patients who failed to at least one line of systemic chemotherapy and anti-PD-1 immunotherapy were enrolled and received cadonilimab plus TPC chemotherapy every 3 weeks for up to 6 cycles, followed by cadonilimab plus capecitabine every 3 weeks for a maximum of 2 years. The primary endpoint was the objective response rate (ORR).

View Article and Find Full Text PDF

Schisandrin B targets CDK4/6 to suppress proliferation and enhance radiosensitivity in nasopharyngeal carcinoma by inducing cell cycle arrest.

Sci Rep

March 2025

The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Affiliated Zhongshan Hospital of Dalian University, No.6 Jiefang Street, Zhongshan District, Dalian, 116001, Liaoning, China.

Nasopharyngeal carcinoma (NPC) is notably prevalent in East and Southeast Asia, where despite advancements in radiotherapy leading to high control rates, challenges like radioresistance and collateral tissue damage remain significant. While Schisandrin B (SchB) has been demonstrated antitumor effects in various tumors, its efficacy in NPC remains unexplored. In this study, we explored the antitumor potential of Sch B on NPC, particularly its effects on cell proliferation and radiosensitivity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!